학술논문

NIRMATRELVIR/RITONAVIR AND TIXAGEVIMAB/CILGAVIMAB AS SARS-COV-2 TREATMENT IN PEDIATRIC AND YOUNG ADULT PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) OR CD19-DIRECTED CAR T-CELL TREATMENT